Lifelong soy consumption improves tamoxifen response in women with breast cancer; however, adding soy to diet after initiating tamoxifen therapy may not provide the same benefits.
For women receiving tamoxifen in the adjuvant setting for early stage breast cancer or as a preventive for high risk of breast cancer, the risk of developing endometrial pathology in those with negative uterine examination findings prior to treatment is very low.
Combining 2 existing chemotherapy drugs, a DNMT1 inhibitor and a histone deacetylase inhibitor, reduced the numbers of cancer stem cells and improved survival in a mouse model.
New study findings presented at SABCS 2015 suggest that BRCAT431 promotes tamoxifen resistance, thereby increasing the clinical risk of recurrence and metastases in breast cancer.
Tamoxifen with ovarian function suppression versus tamoxifen alone as an adjuvant treatment for premenopausal breast cancer: a meta-analysis of published randomized controlled trialsJuly 09, 2015
[OncoTargets and Therapy] This article examines possible survival benefits of ovarian function suppression (OFS) when combined with adjuvant tamoxifen treatment for breast cancer in premenopausal women.
Survival mechanism in breast cancer cells is found to result in poorer outcomes for African American womenMay 06, 2015
The worse outcomes for African American women with estrogen-receptor positive (ER+) breast cancer, when compared with European American patients, appears to be related to a reduced cellular sensitivity to tamoxifen.
Researchers examined the benefits and risks associated with taking drug tamoxifen for breast cancer prevention.
Among premenopausal women with early stage, HR-positive breast cancer, the addition of ovarian suppression to tamoxifen reduced breast cancer recurrence.
The International Breast Cancer Intervention Study-I (IBIS-I) trial found that tamoxifen significantly decreased the incidence of all breast cancers, according to data presented at the 2014 San Antonio Breast Cancer Symposium.
SERMs and aromatase inhibitors have been proven to be excellent agents in the preventive setting for ER-positive breast cancer, but newer agents must be found specifically for ER-negative breast cancers, which mostly occur in premenopausal women.
A gel form of tamoxifen applied to the breasts of women with noninvasive breast cancer reduced the growth of cancer cells to the same degree as the drug taken in oral form but with fewer side effects.
Keeping a light on at night can suppress the body's production of a hormone called melatonin, possibly reducing the effectiveness of the breast-cancer drug tamoxifen, a study suggests.
For rats bearing human breast tumors, exposure to dim light at night made the tumors resistant to the breast cancer drug tamoxifen, according to recently published data.
Researchers have identified genes that may help predict whether a patient with estrogen receptor (ER)-positive breast cancer is likely to benefit from tamoxifen therapy.
A gel containing the drug tamoxifen and applied to the skin was as effective as the pill form in reducing the growth of breast cancer cells in women with noninvasive cancer.
The antimalarial drug hydroxychloroquine (HCQ) reverses resistance to tamoxifen in mice, according to investigators.
For premenopausal women with hormone receptor-positive early breast cancer, exemestane plus ovarian function suppression (OFS) is superior to tamoxifen plus OFS.
A patient on adjuvant endocrine therapy for breast cancer is complaining of hair loss. Could the alopecia be due to her endocrine therapy?
Can the drug paroxetine mesylate (Brisdelle, Paxil) be given to patients taking a chemoprevention drug such as raloxifene (Evista) or any of the aromatase inhibitors?
Researchers have not only confirmed that tamoxifen induces cognitive dysfunction in users, they have also found an existing treatment that can prevent this adverse effect.
MEK1/2 inhibition rescues glial progenitor cells from toxicity; prevents tamoxifen-induced cell death.
Adding to the picture of what prompts breast cancer to form, researchers have found that distant estrogen response elements can act independently of oncogenes to spur tumor development.
A global study of women with inherited mutations in BRCA1 or BRCA2 found that tamoxifen could halve the risk for breast cancer in the contralateral (opposite-side) breast in these high-risk women.
Clinicians should discuss the prophylactic use of tamoxifen as well as two other agents with women 35 years and older and at increased risk of ER-positive breast cancer, per ASCO recommendations.
The addition of BH3 mimetics to standard tamoxifen treatment improved the effectiveness of hormone therapy in luminal B cancers, an aggressive subtype of ER-positive breast cancer.
A biomarker reflecting expression levels of two genes in tumor tissue has been found to predict which patients may be at risk for late recurrence of estrogen receptor (ER)-positive breast cancer, and when adjuvant letrozole therapy may be of benefit.
Single nucleotide polymorphisms (SNPs) in or near the genes ZNF423 and CTSO were associated with breast cancer risk among women who underwent prevention therapy with tamoxifen and raloxifene.
Women at high risk for breast cancer may benefit most from preventive drug therapy, shows a study done for the US Preventive Services Task Force.
The U.S. Preventive Services Task Force recommends that women who are at increased risk of primary breast cancer consider taking preventive medications such as tamoxifen.
Is CYP2D6 genotyping for tamoxifen (Nolvadex) sensitivity before use of the drug beneficial?
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|